PMID: 8601042Sep 1, 1995Paper

Carmeda surface heparinization in neonatal ECMO systems: long-term experiments in a sheep model

Perfusion
K PalmérB Frenckner

Abstract

The thromboresistance in three Carmeda (Stockholm, Sweden) heparin-coated neonatal ECMO systems with a runtime of 45, 56 and 96 hours, respectively, and three noncoated systems with a runtime of 12, 42 and 66 hours, respectively, were compared using a sheep model. The flow rate was 200 ml/min and the activated clotting time (ACT) was kept at approximately 120 seconds. At the end of the experiment, the heparin-coated systems only contained minimal clotting while the controls showed major clotting in the entire system. Fibrin monomers were not detected until after 24 hours in the heparin-coated group, but demonstrated within 60 minutes in the noncoated group. It is concluded that the Carmeda heparin coating has a thromboresistant effect, and may be used to reduce the need for systemic heparinization in ECMO treatment of neonates.

Citations

Jul 19, 2002·Chest Surgery Clinics of North America·Scott K Alpard, Joseph B Zwischenberger
Sep 25, 2014·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Brian W GrayRobert H Bartlett
Mar 28, 2006·The Annals of Thoracic Surgery·Karen L BoothPeter C Laussen
Jun 18, 2014·Journal of Biomaterials Applications·Terry C MajorRobert H Bartlett
Jul 26, 2002·Perfusion·Joseph B Zwischenberger, Scott K Alpard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.